Paragon Biosciences LLC — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Castle Creek Biosciencescastlecreekbio.comin𝕏May 2022 · $112.8M
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
BiotechDeep TechMedical DevicesExton, US
Matthew Gantz(President and Chief Executive Officer)inDavid ChuinMichael TownsleyChristopher J. LarsoninRhea WilliamsinJude Sullivan(Executive Officer)
Co-investorsValor Equity PartnersFidelity InvestmentsHorizon
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.